In 2004, Turner, et al. coined the term “BRCAness” to describe patients who do not have a pathogenic germline variant in BRCA1 or BRCA2 but who have developed a tumor with an impaired ability to perform HR [31]. The gene discussed is BRCA2; the disease is neoplasm.